Sunscreen use and melanocytic nevi in children: a systematic review

Marie-Florence de Maleissye1, Alain Beauchet, Phillippe Saiag

  • 1Research Unit EA 4339 Skin, environment, and cancer, Ambroise Paré University Hospital, University of Versailles-Saint Quentin en Yvelines, Assistance Publique-Hôpitaux de Paris, Boulogne-Billancourt, Paris, France.

Pediatric Dermatology
|September 22, 2012
PubMed

Insights

This review found inconsistent evidence regarding sunscreen use and melanocytic nevi (MN) in children. Most studies showed no protective effect, with some even suggesting a positive association between sunscreen and MN development.

Area of Science:

  • Dermatology
  • Pediatrics
  • Public Health

Background:

  • Melanocytic nevi (MN) are common skin growths in children.
  • Sunscreen use is widely recommended for sun protection.
  • The association between childhood sunscreen use and MN development requires clarification.

Purpose of the Study:

  • To systematically review the scientific literature on the association between melanocytic nevi (MN) in childhood and sunscreen use.
  • To evaluate the evidence for a protective effect of sunscreen against MN development in children.

Main Methods:

  • Systematic review of randomized trials, cohort, and cross-sectional studies.
  • Bibliographic search of MEDLINE and EMBASE databases (November 2008 - January 2009).
  • Inclusion of 15 articles involving 20,743 children; data abstraction by three reviewers.

Main Results:

  • Significant heterogeneity in study methodologies (child age, MN counting, sunscreen assessment) precluded meta-analysis.
  • Twelve of fifteen studies reported no protective effect of sunscreen against MN development.
  • Three studies indicated a lower MN count with sunscreen use, while eight reported a positive association between sunscreen and MN count.

Conclusions:

  • Methodological inconsistencies across studies limit definitive conclusions.
  • Current evidence does not support a protective effect of sunscreen against MN development in children.
  • Disparities in results may be due to differences in MN counts, sun exposure, and application practices in fair-skinned children.

Related Concept Videos

Skin Cancer01:30

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Changes in Skin Color: Clinical Perspectives01:14

Changes in Skin Color: Clinical Perspectives

The first thing a clinician sees is the skin, so the examination of the skin should be part of any thorough physical examination. Most skin disorders are relatively benign, but a few, including melanomas, can be fatal if untreated. A couple of the more noticeable disorders, albinism and vitiligo, affect the appearance of the skin and its accessory organs.
Albinism
Albinism is a genetic disorder that affects (completely or partially) the coloring of skin, hair, and eyes. The defect is primarily...
Pigmentation01:19

Pigmentation

The color of the skin is influenced by a number of pigments, including melanin, carotene, and hemoglobin. Recall that melanin is produced by cells called melanocytes, which are found scattered throughout the stratum basale of the epidermis. The melanin is transferred to the keratinocytes via melanosomes.
Melanin occurs in two primary forms: eumelanin that provides black and brown pigment and pheomelanin that provides red color. Dark-skinned individuals produce more melanin than those with pale...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...